WHAT WE DO
WBB Securities is a leading investment management, investment banking, and equity research firm.  Established in 2001 and headquartered in San Diego, WBB Securities is a registered independent broker-dealer and investment advisor with proprietary trading desks that have market-making capabilities.  WBB Securities has built a nationwide team of respected senior investment and research professionals with a network of branches throughout the U.S., serving institutional and high net worth clients.

The firm also maintains an investment banking and equity research practice focused exclusively in the life sciences niche.  Our investment bank has participated in over 120 transactions leading to $2 billion placed.  Whether raising capital or executing strategic transactions, our banking team is equipped to meet your financial needs and is comprised of some of the most knowledgeable people working in our domain.  Our firm has been singled out for its equity research and analytics year after year from our peers for accuracy and performance by the financial industry's most highly regarded rankings organizations. 

OUR AREAS
INVESTMENT MANAGEMENT

Our Financial Advisors are skilled strategists and experts in financial planning, portfolio construction and investment management.

m&a AND STRATEGIC ADVISORY

We have the relationships and analytics in place to power your M&A needs through our strategic transactions unit.  

INVESTMENT BANKING

Our investment banking practice is focused in the field of life sciences and is comprised of a team of the best specialists in the field.  

institutional sales

Our sales and trading professionals can assist you to meet all of your institutional equity sales requirements.

equity research

We cover the most dynamic life sciences companies in the industry, and are continuously recognized for research performance.

EQUITY Capital Markets

We offer a full spectrum of innovative products and services to meet your capital needs.

LATEST NEWS

VIEW ALL

With Big Pharma In Retreat, Ackman And Novartis Try A New Blueprint For Drug Companies

Yesterday in a move that returned attention to healthcare takeovers, Bill Ackman, CEO of the hedge fund Pershing Square Capital,…
CONTINUE READING

WBB Securities Named Co-Manager on Omeros Corporation Underwriting

Omeros closes $40.25 million in underwritten public offering
CONTINUE READING

A 21st Century Nosocomial Issue with Endoscopes

On 3 January 2014 the results of a year long investigation by the US Centers for Disease Control (CDC) into…
CONTINUE READING

Will Pharma’s Future Be Based On The Carl Icahn Business Model?

For today, the buzz surrounding Carl Icahn derives from his initiative to separate PayPal from eBay. More frequently, people tend…
CONTINUE READING